Repare Therapeutics (RPTX) Competitors $1.59 +0.04 (+2.58%) Closing price 08/22/2025 04:00 PM EasternExtended Trading$1.53 -0.06 (-3.77%) As of 08/22/2025 07:09 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock RPTX vs. ANNX, NMRA, VOR, ALMS, IMMP, TKNO, SCPH, ALLO, SGMT, and SOPHShould you be buying Repare Therapeutics stock or one of its competitors? The main competitors of Repare Therapeutics include Annexon (ANNX), Neumora Therapeutics (NMRA), Vor Biopharma (VOR), Alumis (ALMS), Prima BioMed (IMMP), Alpha Teknova (TKNO), scPharmaceuticals (SCPH), Allogene Therapeutics (ALLO), Sagimet Biosciences (SGMT), and SOPHiA GENETICS (SOPH). These companies are all part of the "pharmaceutical products" industry. Repare Therapeutics vs. Its Competitors Annexon Neumora Therapeutics Vor Biopharma Alumis Prima BioMed Alpha Teknova scPharmaceuticals Allogene Therapeutics Sagimet Biosciences SOPHiA GENETICS Annexon (NASDAQ:ANNX) and Repare Therapeutics (NASDAQ:RPTX) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, media sentiment, valuation, risk, profitability, analyst recommendations, earnings and institutional ownership. Is ANNX or RPTX more profitable? Annexon's return on equity of -70.04% beat Repare Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets AnnexonN/A -70.04% -57.67% Repare Therapeutics N/A -78.25%-66.85% Does the media prefer ANNX or RPTX? In the previous week, Annexon had 7 more articles in the media than Repare Therapeutics. MarketBeat recorded 7 mentions for Annexon and 0 mentions for Repare Therapeutics. Annexon's average media sentiment score of 0.54 beat Repare Therapeutics' score of 0.00 indicating that Annexon is being referred to more favorably in the media. Company Overall Sentiment Annexon Positive Repare Therapeutics Neutral Which has more risk & volatility, ANNX or RPTX? Annexon has a beta of 1.3, suggesting that its stock price is 30% more volatile than the S&P 500. Comparatively, Repare Therapeutics has a beta of 0.93, suggesting that its stock price is 7% less volatile than the S&P 500. Which has preferable earnings and valuation, ANNX or RPTX? Repare Therapeutics has higher revenue and earnings than Annexon. Annexon is trading at a lower price-to-earnings ratio than Repare Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAnnexonN/AN/A-$138.20M-$1.29-1.79Repare Therapeutics$53.48M1.28-$84.69M-$2.58-0.62 Do institutionals and insiders have more ownership in ANNX or RPTX? 85.1% of Repare Therapeutics shares are owned by institutional investors. 11.9% of Annexon shares are owned by insiders. Comparatively, 11.5% of Repare Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth. Do analysts rate ANNX or RPTX? Annexon currently has a consensus price target of $12.50, indicating a potential upside of 441.13%. Repare Therapeutics has a consensus price target of $4.50, indicating a potential upside of 183.02%. Given Annexon's stronger consensus rating and higher probable upside, analysts plainly believe Annexon is more favorable than Repare Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Annexon 0 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.75Repare Therapeutics 0 Sell rating(s) 2 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.50 SummaryAnnexon beats Repare Therapeutics on 10 of the 14 factors compared between the two stocks. Get Repare Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for RPTX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding RPTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart RPTX vs. The Competition Export to ExcelMetricRepare TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$66.59M$3.11B$5.76B$9.58BDividend YieldN/A2.23%4.41%4.10%P/E Ratio-0.6220.8831.1026.05Price / Sales1.28342.28432.51103.82Price / CashN/A43.1937.7358.48Price / Book0.628.129.536.61Net Income-$84.69M-$54.72M$3.26B$265.56M7 Day Performance1.27%2.63%2.10%1.97%1 Month Performance3.92%2.78%2.81%-0.36%1 Year Performance-47.18%11.01%30.56%19.03% Repare Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)RPTXRepare Therapeutics2.2727 of 5 stars$1.59+2.6%$4.50+183.0%-46.5%$66.59M$53.48M-0.62180ANNXAnnexon2.759 of 5 stars$2.35-3.7%$12.50+431.9%-60.2%$267.70MN/A-1.8260NMRANeumora Therapeutics2.3895 of 5 stars$1.64+0.6%$7.14+335.5%-85.9%$263.97MN/A-1.04108VORVor Biopharma2.0188 of 5 stars$2.04-4.7%$6.07+197.4%+135.9%$258.43MN/A-1.24140ALMSAlumis2.6596 of 5 stars$4.85+2.1%$20.17+315.8%-62.5%$258.43MN/A0.00N/AIMMPPrima BioMed1.1554 of 5 stars$1.78+2.9%$7.00+293.3%-26.3%$253.94M$5.14M0.002,021Upcoming EarningsTKNOAlpha Teknova1.8871 of 5 stars$4.41-6.0%$10.00+126.8%-3.5%$250.99M$37.74M-10.50240SCPHscPharmaceuticals4.5463 of 5 stars$4.78+3.9%$14.00+192.9%-5.6%$245.17M$49.97M-2.6430Short Interest ↓ALLOAllogene Therapeutics2.8605 of 5 stars$1.09-0.9%$8.44+674.7%-54.1%$244.07M$20K-0.98310SGMTSagimet Biosciences3.2428 of 5 stars$7.55-1.6%$25.67+240.0%+144.3%$235.28M$2M-4.138SOPHSOPHiA GENETICS2.9803 of 5 stars$3.49+0.6%$8.00+129.2%+2.0%$234.50M$65.17M-7.93520Positive NewsGap Up Related Companies and Tools Related Companies Annexon Alternatives Neumora Therapeutics Alternatives Vor Biopharma Alternatives Alumis Alternatives Prima BioMed Alternatives Alpha Teknova Alternatives scPharmaceuticals Alternatives Allogene Therapeutics Alternatives Sagimet Biosciences Alternatives SOPHiA GENETICS Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:RPTX) was last updated on 8/23/2025 by MarketBeat.com Staff From Our PartnersBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredThe $7 company helping Nvidia build the world’s first trillion-dollar robot …Michael Robinson has been at the forefront of the technology market for over 40 years. Spotting some profit...Weiss Ratings | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredAmazon’s big Bitcoin embarrassmentBitcoin just passed Amazon in total market cap — but most investors are missing the bigger opportunity. Whi...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Repare Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Repare Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access